Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Receives Average Recommendation of

0
5


Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) has been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $12.67.

Several equities analysts have commented on AGLE shares. BidaskClub raised shares of Aeglea BioTherapeutics from a “sell” rating to a “hold” rating in a report on Thursday, September 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Aeglea BioTherapeutics in a report on Monday, August 10th. Lifesci Capital reissued an “outperform” rating on shares of Aeglea BioTherapeutics in a report on Friday, October 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (down previously from $17.00) on shares of Aeglea BioTherapeutics in a research report on Monday, November 9th.

A number of institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can increased its holdings in Aeglea BioTherapeutics by 219.1% during the 2nd quarter. Bank of Montreal Can now owns 5,399 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 3,707 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Aeglea BioTherapeutics by 414.5% in the third quarter. BNP Paribas Arbitrage SA now owns 9,945 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 8,012 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of Aeglea BioTherapeutics during the 3rd quarter valued at $75,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of Aeglea BioTherapeutics during the 3rd quarter worth $89,000. Finally, JPMorgan Chase & Co. grew its position in Aeglea BioTherapeutics by 10.8% in the third quarter. JPMorgan Chase & Co. now owns 15,654 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 1,531 shares in the last quarter. Institutional investors and hedge funds own 77.77% of the company’s stock.

(Ad)

According to a former hedge fund manager with 500,000 followers around the world, the next three months could determine who will become fabulously wealthy in 2021 – and who won’t. It has nothing to do with the COVID-19 crisis. Instead, it’s a huge stock market trend that was already creating millionaires before the pandemic hit. Now, it’s been accelerated.

NASDAQ AGLE opened at $9.01 on Friday. Aeglea BioTherapeutics has a 12-month low of $3.50 and a 12-month high of $11.38. The firm has a 50-day moving average price of $8.11 and a two-hundred day moving average price of $7.98. The company has a market capitalization of $431.91 million, a P/E ratio of -4.72 and…



Read More: Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Receives Average Recommendation of

Leave a reply